CA
NZ
UK
AU
IND
US
Few micro-cap medical device companies have had a busier summer than Intelligent Bio Solutions Inc. (NASDAQ:INBS). Since late July the New York-based company has ticked off, one by one, the studies it needs before its first substantive US Food and Drug Administration filing.
Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) is one of the smallest clinical-stage eye-disease companies on the exchange, yet it runs two Phase 2 retinal trials while spending remarkably little of its own money.
Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a micro-cap, clinical-stage biotechnology company that has spent 2026 turning a small skin-cancer study into a real development programme. In eight weeks it has begun commercial-scale manufacturing of its lead drug, reported second-quarter results, added a dermatologist to its …
Akari Therapeutics Plc (NASDAQ:AKTX) has spent 2026 rebuilding itself around one idea: a cancer-drug payload that attacks tumours by jamming the machinery cells use to edit their own genetic instructions.
BioCardia, Inc. (NASDAQ:BCDA) has done something small-cap cell therapy developers rarely manage: turned years of clinical work into a dated regulatory filing. The company is preparing a marketing application in Japan for CardiAMP, its autologous cell therapy for ischemic heart failure, in the fourth …
Chemomab Therapeutics Ltd. (NASDAQ:CMMB) spent years building a case for nebokitug, its experimental antibody for a rare and untreatable liver disease. In July 2026 it agreed to hand the wheel to someone else.
Few micro-cap biotechs get a second act as clean as the one Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) has written. Less than three years after Nasdaq removed it from the exchange, the shares trade on theNasdaq Capital Marketagain, theBalance Sheetholds about $62 million, and the lead …
FibroBiologics, Inc. (NASDAQ:FBLG) is a Houston-based clinical-stage biotechnology company building therapies from fibroblasts, the connective-tissue cells that make collagen and the other proteins the body uses to rebuild damaged tissue. Listed since January 2024, it spent most of its short public life as a …
For years, PDS Biotechnology Corporation (NASDAQ:PDSB) has been defined by one asset: Versamune HPV, or PDS0101, an investigational immunotherapy for HPV16-positive head and neck cancer. On 11 August 2026 the Princeton, New Jersey company told shareholders it would stop funding that programme's pivotal study …
Soligenix, Inc. (NASDAQ:SNGX) has spent 2026 rebuilding itsInvestmentcase from the ground up. For years the Princeton, New Jersey biotech pointed investors to HyBryte, a synthetic hypericin activated by visible light, in cutaneous T-cell lymphoma, a rare cancer of white blood cells that appears as …
Please wait processing your request...